Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04581629 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
A Phase 2 study, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04581629 is a Phase 2 study that has completed, run by Calcilytix Therapeutics, Inc., a BridgeBio company. The registered enrollment target is 13 participants.
The verdict
NCT04581629, a Phase 2 study, has completed, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Interventions
- DRUG Encaleret
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-09-20 |
| Est. Completion | 2023-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04581629
The ClinicalTrials.gov registry entry for NCT04581629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Encaleret is the first listed.
NCT04581629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04581629 about?
NCT04581629 is a clinical study titled "Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1". The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
What is the current status of trial NCT04581629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-09-20. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT04581629?
The interventions under investigation include: Encaleret (DRUG).
Who is sponsoring clinical trial NCT04581629?
This trial is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.